Lack of in vitro cross-reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia

Sherif Farag, Helen Savoia, Cindy J. O'Malley, Katherine M. McGrath

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Alternative anticoagulation in patients with heparin-induced thrombocytopenia (HIT) is often problematic. The relatively high cross- reactivity rate reported for the low-molecular-weight heparins (LMWH) has discouraged their use in this setting. This study has investigated the safety of using the LMWH Fragmin, based on a negative heparin-dependent platelet aggregation test using the latter, in patients with proven HIT. Fifty-three evaluable patients with clinical and laboratory evidence of HIT were evaluated for cross-reactivity with Fragmin using a Fragmin-dependent platelet aggregation test. In 20 of 38 patients who showed no in vitro cross- reactivity, Fragmin was substituted for unfractionated heparin. The outcome of these 20 patients was evaluated and compared to that of the remaining 33 patients, in whom anticoagulates were ceased or warfarin or Orgaran was used. Eighteen of 20 patients treated with Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 57.9 ± 4.7 x 109/l within 2.8 ± 0.29 days following substitution of Fragmin for unfractionated heparin. Twenty- eight of the 33 remaining patients who did not receive Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 53.0 ± 4.8 x 109/l within 3.0 ± 0.29 days. In seven patients (two treated with Fragmin), response could not be evaluated due to death within 36 h of cessation of heparin or discharge from hospital. The results indicate that in vitro cross- reactivity testing employing a heparin-dependent platelet aggregation assay can be safely used to select patients with HIT for further anticoagulation with LMWH.

Original languageEnglish (US)
Pages (from-to)58-62
Number of pages5
JournalClinical and Applied Thrombosis/Hemostasis
Volume3
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Dalteparin
Low Molecular Weight Heparin
Thrombocytopenia
Heparin
Safety
Platelet Aggregation
Platelet Count
In Vitro Techniques
Warfarin

Keywords

  • Cross-reactivity
  • Fragmin
  • Heparin-induced thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Lack of in vitro cross-reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia. / Farag, Sherif; Savoia, Helen; O'Malley, Cindy J.; McGrath, Katherine M.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 3, No. 1, 01.1997, p. 58-62.

Research output: Contribution to journalArticle

@article{57384899c18b44e4a0e7e74e2b7e9aa4,
title = "Lack of in vitro cross-reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia",
abstract = "Alternative anticoagulation in patients with heparin-induced thrombocytopenia (HIT) is often problematic. The relatively high cross- reactivity rate reported for the low-molecular-weight heparins (LMWH) has discouraged their use in this setting. This study has investigated the safety of using the LMWH Fragmin, based on a negative heparin-dependent platelet aggregation test using the latter, in patients with proven HIT. Fifty-three evaluable patients with clinical and laboratory evidence of HIT were evaluated for cross-reactivity with Fragmin using a Fragmin-dependent platelet aggregation test. In 20 of 38 patients who showed no in vitro cross- reactivity, Fragmin was substituted for unfractionated heparin. The outcome of these 20 patients was evaluated and compared to that of the remaining 33 patients, in whom anticoagulates were ceased or warfarin or Orgaran was used. Eighteen of 20 patients treated with Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 57.9 ± 4.7 x 109/l within 2.8 ± 0.29 days following substitution of Fragmin for unfractionated heparin. Twenty- eight of the 33 remaining patients who did not receive Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 53.0 ± 4.8 x 109/l within 3.0 ± 0.29 days. In seven patients (two treated with Fragmin), response could not be evaluated due to death within 36 h of cessation of heparin or discharge from hospital. The results indicate that in vitro cross- reactivity testing employing a heparin-dependent platelet aggregation assay can be safely used to select patients with HIT for further anticoagulation with LMWH.",
keywords = "Cross-reactivity, Fragmin, Heparin-induced thrombocytopenia",
author = "Sherif Farag and Helen Savoia and O'Malley, {Cindy J.} and McGrath, {Katherine M.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "3",
pages = "58--62",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Lack of in vitro cross-reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia

AU - Farag, Sherif

AU - Savoia, Helen

AU - O'Malley, Cindy J.

AU - McGrath, Katherine M.

PY - 1997/1

Y1 - 1997/1

N2 - Alternative anticoagulation in patients with heparin-induced thrombocytopenia (HIT) is often problematic. The relatively high cross- reactivity rate reported for the low-molecular-weight heparins (LMWH) has discouraged their use in this setting. This study has investigated the safety of using the LMWH Fragmin, based on a negative heparin-dependent platelet aggregation test using the latter, in patients with proven HIT. Fifty-three evaluable patients with clinical and laboratory evidence of HIT were evaluated for cross-reactivity with Fragmin using a Fragmin-dependent platelet aggregation test. In 20 of 38 patients who showed no in vitro cross- reactivity, Fragmin was substituted for unfractionated heparin. The outcome of these 20 patients was evaluated and compared to that of the remaining 33 patients, in whom anticoagulates were ceased or warfarin or Orgaran was used. Eighteen of 20 patients treated with Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 57.9 ± 4.7 x 109/l within 2.8 ± 0.29 days following substitution of Fragmin for unfractionated heparin. Twenty- eight of the 33 remaining patients who did not receive Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 53.0 ± 4.8 x 109/l within 3.0 ± 0.29 days. In seven patients (two treated with Fragmin), response could not be evaluated due to death within 36 h of cessation of heparin or discharge from hospital. The results indicate that in vitro cross- reactivity testing employing a heparin-dependent platelet aggregation assay can be safely used to select patients with HIT for further anticoagulation with LMWH.

AB - Alternative anticoagulation in patients with heparin-induced thrombocytopenia (HIT) is often problematic. The relatively high cross- reactivity rate reported for the low-molecular-weight heparins (LMWH) has discouraged their use in this setting. This study has investigated the safety of using the LMWH Fragmin, based on a negative heparin-dependent platelet aggregation test using the latter, in patients with proven HIT. Fifty-three evaluable patients with clinical and laboratory evidence of HIT were evaluated for cross-reactivity with Fragmin using a Fragmin-dependent platelet aggregation test. In 20 of 38 patients who showed no in vitro cross- reactivity, Fragmin was substituted for unfractionated heparin. The outcome of these 20 patients was evaluated and compared to that of the remaining 33 patients, in whom anticoagulates were ceased or warfarin or Orgaran was used. Eighteen of 20 patients treated with Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 57.9 ± 4.7 x 109/l within 2.8 ± 0.29 days following substitution of Fragmin for unfractionated heparin. Twenty- eight of the 33 remaining patients who did not receive Fragmin increased their platelet count by ≤50 x 109/l from a mean nadir of 53.0 ± 4.8 x 109/l within 3.0 ± 0.29 days. In seven patients (two treated with Fragmin), response could not be evaluated due to death within 36 h of cessation of heparin or discharge from hospital. The results indicate that in vitro cross- reactivity testing employing a heparin-dependent platelet aggregation assay can be safely used to select patients with HIT for further anticoagulation with LMWH.

KW - Cross-reactivity

KW - Fragmin

KW - Heparin-induced thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0031421650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031421650&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 58

EP - 62

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 1

ER -